Mariane De Montalembert1, Miguel R Abboud2, Anne Fiquet3, Adlette Inati4, Jeffrey D Lebensburger5, Normeen Kaddah6, Galila Mokhtar7, Antonio Piga8, Natasha Halasa9, Baba Inusa10, David C Rees11, Paul T Heath12, Paul Telfer13, Catherine Driscoll14, Sami Al Hajjar15, Alberto Tozzi16, Qin Jiang17, Emilio A Emini18, William C Gruber18, Alejandra Gurtman18, Daniel A Scott18. 1. Hôpital Necker-Enfants Malades, Service de Pédiatrie, Paris, France. 2. Department of Pediatrics and Adolescent Medicine, American University of Beirut, Beirut, Lebanon. 3. Vaccine Research, Pfizer Ltd, Tadworth, Berkshire, UK. 4. RHUH, Rafic Hariri University Hospital, Beirut, Lebanon. 5. University of Alabama at Birmingham, Birmingham, Alabama. 6. Pediatric Cairo University Hospital (Abu Elreesh - Almoneera), Egypt. 7. Hematology unit, Children Hospital, Ain Shams University, Cairo, Egypt. 8. Ospedale San Luigi Gonzaga, Orbassano, Torino University, Italy. 9. Vanderbilt University Medical Center, Nashville, Tennessee. 10. Evelina Children's Hospital, St Thomas' Hospital, London, UK. 11. King's College Hospital, London, UK. 12. Vaccine Institute, St Georges, University of London, London, UK. 13. Royal London Hospital, London, UK. 14. Children's Hospital at Montefiore, Bronx, New York. 15. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. 16. Unità Operativa di Epidemiologia Ospedale Bambino Gesù, Roma, Italy. 17. Vaccines, Pfizer Inc, Collegeville, Pennsylvania. 18. Vaccine Research, Pfizer Inc, Pearl River, New York.
Abstract
BACKGROUND: A large population of older children with sickle cell disease (SCD) is currently vaccinated with only 23-valent pneumococcal polysaccharide vaccine (PPSV23). In immunocompetent adults, PPSV23 vaccination reduces immune responses to subsequent vaccination with a pneumococcal vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13), which addresses this limitation, may offer an advantage to this population at high risk of pneumococcal disease. PROCEDURE: Children with SCD 6-17 years of age previously vaccinated with PPSV23 at least 6 months before study enrollment received two doses of PCV13 6 months apart. Anti-pneumococcal polysaccharide immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured before, 1 month after each administration, and 1 year after the second administration. RESULTS: Following each PCV13 administration, IgG GMCs and OPA GMTs significantly increased, and antibody levels after doses 1 and 2 were generally comparable. Antibody levels declined over the year following dose 2. At 1 year after the second administration, OPA GMTs for all and IgG GMCs for most serotypes remained above pre-vaccination levels. Most adverse events were due to vaso-occlusive crises, a characteristic of the underlying condition of SCD. CONCLUSIONS: Children with SCD who were previously vaccinated with PPSV23 responded well to 1 PCV13 dose, and a second dose did not increase antibody response. PCV13 antibodies persisted above pre-vaccination levels for all serotypes 1 year after dose 2. Children with SCD may benefit from at least one dose of PCV13.
BACKGROUND: A large population of older children with sickle cell disease (SCD) is currently vaccinated with only 23-valent pneumococcalpolysaccharide vaccine (PPSV23). In immunocompetent adults, PPSV23 vaccination reduces immune responses to subsequent vaccination with a pneumococcal vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13), which addresses this limitation, may offer an advantage to this population at high risk of pneumococcal disease. PROCEDURE: Children with SCD 6-17 years of age previously vaccinated with PPSV23 at least 6 months before study enrollment received two doses of PCV13 6 months apart. Anti-pneumococcalpolysaccharide immunoglobulin G (IgG) geometric mean concentrations (GMCs) and opsonophagocytic activity (OPA) geometric mean titers (GMTs) were measured before, 1 month after each administration, and 1 year after the second administration. RESULTS: Following each PCV13 administration, IgG GMCs and OPA GMTs significantly increased, and antibody levels after doses 1 and 2 were generally comparable. Antibody levels declined over the year following dose 2. At 1 year after the second administration, OPA GMTs for all and IgG GMCs for most serotypes remained above pre-vaccination levels. Most adverse events were due to vaso-occlusive crises, a characteristic of the underlying condition of SCD. CONCLUSIONS:Children with SCD who were previously vaccinated with PPSV23 responded well to 1 PCV13 dose, and a second dose did not increase antibody response. PCV13 antibodies persisted above pre-vaccination levels for all serotypes 1 year after dose 2. Children with SCD may benefit from at least one dose of PCV13.
Authors: Jeffrey D Lebensburger; Prasannalaxmi Palabindela; Thomas H Howard; Daniel I Feig; Inmaculada Aban; David J Askenazi Journal: Pediatr Nephrol Date: 2016-03-24 Impact factor: 3.714
Authors: Steven M Szczepanek; Sean Roberts; Kara Rogers; Christina Cotte; Alexander J Adami; Sonali J Bracken; Sharon Salmon; Eric R Secor; Roger S Thrall; Biree Andemariam; Dennis W Metzger Journal: PLoS One Date: 2016-02-24 Impact factor: 3.240
Authors: Jing Jing Chen; Lin Yuan; Zhen Huang; Nian Min Shi; Yu Liang Zhao; Sheng Li Xia; Guo Hua Li; Rong Cheng Li; Yan Ping Li; Shu Yuan Yang; Jie Lai Xia Journal: BMJ Open Date: 2016-10-19 Impact factor: 2.692